Most refusals trace to one of six things: the drug is absent from the plan’s list, prior authorization has not been granted, a step therapy or quantity rule is unmet, the prescription is written for a use the product is not licensed for, the pharmacy is outside the network, or the enrollment record is wrong. The reason determines the fix, and guessing wastes weeks.
A rejection at the counter is not the same as a denial
When a pharmacist says the claim did not go through, that is the plan’s claims system returning a code. It is fast, it is often thin on detail, and it is not the formal decision that carries appeal rights. Medicare enrollees have the right to ask the plan for a coverage determination, orally or in writing, to establish whether a drug is covered. Until that request is made and answered, there is nothing to challenge. People lose months at this step, retrying the same prescription at the same counter and getting the same code.
The second thing worth separating is who is refusing. A standalone drug plan and a Medicare Advantage plan with drug coverage each run their own drug list and their own review desk, and the plan named on the card is the party that answers. Original Medicare is not in this conversation at all for a self-injected outpatient drug.
Reason one: the drug is not on the plan’s list
Every Part D plan builds its own formulary. Plans must cover a wide range of drugs and must include most drugs in protected classes such as cancer, HIV, antidepressant, antipsychotic, anticonvulsant and transplant immunosuppressant therapies. Diabetes drugs are not a protected class, so a plan can decline to list any particular one. If Mounjaro is absent, the answer is a formulary exception request, and the prescriber has to supply a supporting statement explaining why the listed alternatives will not work.
Reason two: the use does not match the license
This is the reason that surprises people most, and it is the hardest to argue around. Mounjaro is approved to improve glycemic control in adults and pediatric patients aged 10 and older with type 2 diabetes, as an adjunct to diet and exercise. Nothing else. The tirzepatide product licensed for weight reduction and long-term weight maintenance, and separately for moderate to severe obstructive sleep apnea in adults with obesity, is Zepbound. A claim submitted for Mounjaro with an obesity diagnosis behind it is asking a plan to pay for an unapproved use, and plans deny those routinely.
Medicare’s short-term GLP-1 Bridge demonstration, which began July 1, 2026, does not solve this either. CMS excludes people with type 2 diabetes from the demonstration on the grounds that their indication belongs with the Part D plan, and the products CMS lists for it are Foundayo, Wegovy and the Zepbound KwikPen rather than Mounjaro. Anyone relying on that program should confirm its current terms directly with Medicare, since it carries a stated end date of December 31, 2027 and CMS has revised parts of it already.
Reason three: a utilization rule was never satisfied
Plans apply prior authorization, step therapy and quantity limits, and each produces a refusal that looks identical at the register. Step therapy asks that a cheaper listed drug be tried first. Quantity limits cap how much is covered in a period. Prior authorization asks the prescriber to document that the plan’s conditions are met before anything is paid. All three can be challenged through an exception request supported by a prescriber statement, and none of them resolve on their own.
What each reason actually needs
| Reason given | What it means | The move that answers it |
|---|---|---|
| Not on the drug list | The plan does not cover this product | Formulary exception with prescriber supporting statement |
| Prior authorization required | Conditions exist and are undocumented | Prescriber submits the plan’s authorization request |
| Step therapy | A listed alternative has not been tried | Exception citing prior failure or contraindication |
| Quantity limit exceeded | More was billed than the plan covers per period | Exception on medical grounds, or corrected day supply |
| Non-formulary use | Diagnosis does not match the license | Reassess the product with the prescriber |
| Pharmacy or eligibility problem | Out-of-network, wrong card, coverage not active | Fix the record, then resubmit |
The administrative denials nobody expects
A meaningful share of refusals have nothing to do with the drug. A new plan may not have loaded yet, which is why Medicare tells enrollees to bring the acknowledgement letter or enrollment confirmation number to the pharmacy before the card arrives. The pharmacy may sit outside the plan’s network. An approval granted last year may have quietly expired. A drug list can change mid-year under Medicare’s rules, and while the plan must notify members whose drugs are affected, the notice is easy to miss in a stack of mail. Prescribers who appear on the CMS Preclusion List cannot have their prescriptions covered under Part D at all.
Where cash routes sit in this picture
Some people give up on the plan and buy outside it. Telehealth practices such as Ro, Hims and Hers, and formblends.com publish flat monthly prices for compounded tirzepatide and semaglutide following a clinician review, which is a real option and worth understanding accurately. Compounded tirzepatide is not Mounjaro and is not FDA-approved, meaning no agency has evaluated it for safety, effectiveness or manufacturing quality, and Part D will not pay for it under any circumstances. Reviews of federal adverse event data have documented safety signals with compounded GLP-1 products, and dosing errors have been reported to poison control centers.
The financial point is easy to miss on a fixed income. Anything bought outside the plan does not count toward the Part D deductible or the annual out-of-pocket threshold, which is $2,100 in 2026 and triggers catastrophic coverage for the rest of the year once reached. A year of cash subscriptions leaves that counter at zero.
The branded drug is a separate purchase with a separate set of names behind it. People who specifically want FDA-approved Mounjaro rather than a compounded copy tend to look at manufacturer-linked and telehealth channels that price the real product, and providers such as HealthRX and LillyDirect post what a branded month of Mounjaro runs before insurance. It costs more than a compounded subscription and still lands outside the Part D counter, so the accumulation problem does not disappear.
Frequently asked questions
Does a pharmacy rejection start the appeal clock?
No. The clock starts when the plan issues a written decision on a coverage determination request. A counter rejection is a claims message, not a determination. Ask the plan directly for the decision in writing, keep the notice, and work from the deadline printed on it rather than the date at the pharmacy.
Why did the same prescription pay last month and reject this month?
Three common causes: an authorization reached its end date, the plan changed its drug list mid-year under Medicare’s rules, or the benefit moved into a new cost stage. Plans must notify members about drug list changes affecting drugs they take, so ask which of the three applies before resubmitting.
Can Part B pay when Part D refuses?
Almost never for this drug. Part B covers a limited set of outpatient drugs, mostly those given by a provider, used with covered equipment, or falling into named categories such as immunosuppressants after a covered transplant. A self-administered weekly injection filled at a retail pharmacy sits in Part D.
Does a denial for one tirzepatide product apply to the other?
No. Mounjaro and Zepbound are separate products with separate licensed uses, and plans review them separately. A refusal on one says nothing about the other. Each has its own formulary status, its own rules, and its own exception path if it is not listed.
